XML 43 R26.htm IDEA: XBRL DOCUMENT
v3.25.3

Business Segment Information | 12 Months Ended
--- | ---
Jul. 31, 2025
Business Segment Information [Abstract] |
BUSINESS SEGMENT INFORMATION | NOTE 22 – BUSINESS SEGMENT INFORMATION The Company conducts business as three operating segments, Healthcare, Infusion Technology and Real Estate. The Company’s reportable segments are distinguished by types of service, customers and methods used to provide their services. The operating results of these business segments are regularly reviewed by the Company’s Chief Financial Officer who is the chief operating decision-maker (“CODM”). The accounting policies of the segments are the same as the accounting policies of the Company as a whole. The Company evaluates the performance of its Healthcare segment based primarily on results of clinical trials and loss from operations, and the Infusion Technology and Real Estate segments based primarily on revenues and income (loss) from operations. The CODM uses these measures to allocate the Company’s resources. The CODM does not review any measure of significant segment expenses which differ from the level of reporting reflected in the tables below. Currently, the CODM does not review assets in evaluating the results of the operating segments, and therefore, such information is not presented. The Healthcare segment is comprised of a majority equity interest in LipoMedix, Barer, Cornerstone, Cyclo, and Rafael Medical Devices. Following the Cyclo Merger, the Healthcare segment generated $515 thousand of product revenue during the year ended July 31, 2025. The Real Estate segment consists of the Company’s real estate holdings, which are currently comprised of a portion of one commercial building in Israel. The Infusion Technology segment is comprised of a majority equity interest in Day Three. Revenues associated with the Infusion Technology segment include Infusion Technology revenue derived from Day Three’s Unlokt technology. Operating results for the business segments of the Company are as follows:
(in thousands) |  | Healthcare |  |  | Infusion Technology |  |  | Real Estate |  |  | Total |
Year Ended July 31, 2025 |  |  |  |  |  |  |  |  |  |  |  |
Infusion technology revenue |  | $ | — |  |  | $ | 93 |  |  | $ | — |  |  | $ | 93 |
Rental – Third Party |  |  | — |  |  |  | — |  |  |  | 197 |  |  |  | 197 |
Rental – Related Party |  |  | — |  |  |  | — |  |  |  | 112 |  |  |  | 112 |
Product revenue |  |  | 515 |  |  |  | — |  |  |  | — |  |  |  | 515 |
COSTS AND EXPENSES |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Infusion Technology revenue |  |  | — |  |  |  | (106 | ) |  |  | — |  |  |  | (106 | )
Cost of product revenue |  |  | (28 | ) |  |  | — |  |  |  | — |  |  |  | (28 | )
General and administrative |  |  | (13,165 | ) |  |  | (320 | ) |  |  | (296 | ) |  |  | (13,781 | )
Research and development |  |  | (12,568 | ) |  |  | (255 | ) |  |  | — |  |  |  | (12,823 | )
Depreciation and amortization |  |  | (48 | ) |  |  | (177 | ) |  |  | (63 | ) |  |  | (288 | )
Loss on impairment of goodwill |  |  | — |  |  |  | (3,050 | ) |  |  | — |  |  |  | (3,050 | )
Loss from operations |  | $ | (25,294 | ) |  | $ | (3,815 | ) |  | $ | (50 | ) |  | $ | (29,159 | )
(in thousands) |  | Healthcare |  |  | Infusion Technology |  |  | Real Estate |  |  | Total |
Year Ended July 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Infusion technology revenue |  | $ | — |  |  | $ | 355 |  |  | $ | — |  |  | $ | 355 |
Rental – Third Party |  |  | — |  |  |  | — |  |  |  | 174 |  |  |  | 174 |
Rental – Related Party |  |  | — |  |  |  | — |  |  |  | 108 |  |  |  | 108 |
COSTS AND EXPENSES |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of Infusion Technology revenue |  |  | — |  |  |  | (154 | ) |  |  | — |  |  |  | (154 | )
General and administrative |  |  | (8,338 | ) |  |  | (374 | ) |  |  | (142 | ) |  |  | (8,854 | )
Research and development |  |  | (3,668 | ) |  |  | (502 | ) |  |  | — |  |  |  | (4,170 | )
In-process research and development |  |  | (89,861 | ) |  |  | — |  |  |  | — |  |  |  | (89,861 | )
Depreciation and amortization |  |  | (165 | ) |  |  | — |  |  |  | (60 | ) |  |  | (225 | )
(Loss) income from operations |  | $ | (102,032 | ) |  | $ | (675 | ) |  | $ | 80 |  |  | $ | (102,627 | )
A reconciliation between loss from operations by reportable segment to consolidated net loss before income taxes for the years ended July 31, 2025 and 2024, is as follows:
(in thousands) |  | July 31, 2025 |  |  | July 31, 2024 |
(Loss) income from operations by segment |  |  |  |  |  |
Healthcare |  | $ | (25,294 | ) |  | $ | (102,032 | )
Infusion Technology |  |  | (3,815 | ) |  |  | (675 | )
Real Estate |  |  | (50 | ) |  |  | 80 |
Total |  |  | (29,159 | ) |  |  | (102,627 | )
Reconciliation to loss before income taxes: |  |  |  |  |  |  |  |
Interest income |  |  | 1,996 |  |  |  | 2,383 |
Loss on initial investment in Day Three upon acquisition |  |  | — |  |  |  | (1,633 | )
Realized gain on available-for-sale securities |  |  | 178 |  |  |  | 1,772 |
Realized loss on investment in equity securities |  |  | — |  |  |  | (46 | )
Realized gain on investment - Cyclo |  |  | — |  |  |  | 424 |
Unrealized (loss) gain on investment - Cyclo |  |  | (5,144 | ) |  |  | 37 |
Unrealized (loss) gain on convertible notes receivable, due from Cyclo |  |  | (719 | ) |  |  | 1,191 |
Unrealized gain on investment - Hedge Funds |  |  | — |  |  |  | 63 |
Recovery of receivables from Cornerstone |  |  | — |  |  |  | 31,305 |
Interest expense |  |  | (658 | ) |  |  | (248 | )
Other income, net |  |  | 310 |  |  |  | 118 |
Loss before income taxes |  | $ | (33,196 | ) |  | $ | (67,261 | )
Geographic Information Healthcare Segment Revenue from the Healthcare segment was generated primarily from customers located in the United States. During the year ended July 31, 2025, approximately $30 thousand of product revenue from the Healthcare Segment was generated from customers located in Canada. Infusion Technology Segment Revenue from the Infusion Technology segment was generated entirely from customers located in the United States. Real Estate Segment Revenue from the Real Estate segment was generated entirely from tenants located in Israel. Assets Net property, plant, and equipment and total assets summarized by geographic area are as follows:
(in thousands) |  | United States |  |  | Israel |  |  | Total |
July 31, 2025 |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | $ | 321 |  |  | $ | 1,275 |  |  | $ | 1,596 |
Total assets |  |  | 111,954 |  |  |  | 2,155 |  |  |  | 114,109 |
July 31, 2024 |  |  |  |  |  |  |  |  |  |  |  |
Property, plant and equipment, net |  | $ | 783 |  |  | $ | 1,337 |  |  | $ | 2,120 |
Total assets |  |  | 93,434 |  |  |  | 3,398 |  |  |  | 96,832 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration